SIRPA and neoplasm: More importantly, we found that in the HRisk group, the immune checkpoints (SIRPA, LILRB1, SIGLEC10) of tumor associated macrophages involved in tumor antigen recognition disorders increased significantly (Fig. 6E, F), releasing anti phagocytic signals and negatively regulating the phagocytic function of macrophages.